USCAP 2026 Hematopathology Update

USCAP 2026 Hematopathology Update

Advanced Hematopathology Review | WHO 5th Edition, ICC, Morphology, NGS & Ancillary Testing

Stay current with the rapidly evolving field of hematopathology with USCAP 2026 Hematopathology Update, an advanced educational program designed for practicing academic and community pathologists and pathologists-in-training.

As hematopathology diagnosis continues to incorporate sophisticated technologies such as next-generation sequencing (NGS), accurate morphologic interpretation remains fundamental to the diagnosis of lymphoid and myeloid neoplasms as well as reactive and non-neoplastic hematolymphoid conditions.

This expert-led course provides practical guidance on applying the 5th Edition World Health Organization (WHO) Classification and the International Consensus Classification (ICC) in contemporary diagnostic practice. The program addresses both lymphoid and myeloid disorders and emphasizes the integration of morphology, clinical findings, and ancillary studies to reach accurate and efficient diagnoses.

Product Details

• Course: USCAP 2026 Hematopathology Update
• Provider: USCAP
• Official Course Dates: June 14–17, 2026
• Official Venue: Reykjavik, Iceland
• Language: English
• Educational Level: Advanced
• Focus: Hematopathology, Lymphoid Neoplasms, Myeloid Neoplasms, WHO Classification, ICC, Ancillary Testing

Course Overview

Modern hematopathology diagnosis is increasingly complex, requiring pathologists to integrate morphology with immunophenotyping, molecular testing, cytogenetics, and next-generation sequencing.

Despite these advances, morphology remains a cornerstone of accurate diagnosis. Correct morphologic interpretation helps determine which ancillary studies are appropriate, avoid unnecessary testing, and correctly interpret the results within the clinical context.

USCAP 2026 Hematopathology Update provides expert instruction focused on the practical application of current classification systems and diagnostic criteria. Faculty address the WHO 5th Edition Classification and International Consensus Classification (ICC), including situations where the two systems may result in discrepant diagnoses.

The course includes dedicated sessions on both lymphoid and myeloid neoplasms, helping hematopathologists translate contemporary classification criteria into everyday diagnostic practice.

What You’ll Learn

Participants will strengthen their ability to:

• Recognize morphologic features of lymphoid and myeloid neoplasms.
• Identify reactive and non-neoplastic hematolymphoid proliferations.
• Apply WHO 5th Edition diagnostic criteria.
• Apply International Consensus Classification (ICC) criteria.
• Navigate discrepancies between WHO and ICC classifications.
• Determine when ancillary testing is appropriate.
• Select appropriate ancillary studies based on morphologic and clinical findings.
• Interpret ancillary test results in the context of the complete case.
• Integrate morphology, clinical information, and ancillary studies into the final diagnosis.
• Use diagnostic testing more efficiently and cost-effectively.

Key Topics

Hematolymphoid Morphology

Morphology remains essential for identifying and classifying hematologic disorders.

The program covers:

• Myeloid neoplasms
• Lymphoid neoplasms
• Reactive hematolymphoid proliferations
• Common hematologic entities
• Less common neoplasms
• Morphologic diagnostic features

WHO 5th Edition Classification

Develop practical skills in applying the 5th Edition World Health Organization Classification to hematopoietic neoplasms and incorporating its diagnostic criteria into routine practice.

International Consensus Classification (ICC)

Understand how the ICC approaches hematopoietic neoplasms and how to address cases where WHO and ICC classifications may produce different diagnostic conclusions.

Ancillary Testing

Learn how morphology and clinical findings should guide additional testing.

Topics include:

• When to order ancillary studies
• Selecting appropriate tests
• Cost-effective diagnostic testing
• Interpretation of ancillary results
• Integration of test results with morphology
• Incorporation of findings into the final diagnosis

Next-Generation Sequencing

Explore the increasingly important role of advanced molecular tools, including next-generation sequencing (NGS), while maintaining morphology as a critical component of diagnostic evaluation.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

• Describe the morphologic features of common and less common myeloid and lymphoid neoplasms and reactive non-neoplastic hematolymphoid proliferations.
• Apply the diagnostic criteria of the WHO 5th Edition and ICC for hematopoietic neoplasms in clinical practice, including management of cases where the two classifications produce discrepant diagnoses.
• Determine when ancillary studies should be ordered based on morphologic and clinical findings, select appropriate studies in a cost-effective manner, and interpret and integrate their results into the final diagnosis.

Course Highlights

✔ Expert-led hematopathology education
✔ Lymphoid and myeloid neoplasm sessions
✔ WHO 5th Edition Classification
✔ International Consensus Classification (ICC)
✔ Morphology-focused diagnosis
✔ Reactive hematolymphoid conditions
✔ Ancillary testing strategies
✔ Next-generation sequencing concepts
✔ Clinical and morphologic integration
✔ Cost-effective diagnostic testing
✔ Practical diagnostic application

Target Audience

This educational activity is specifically designed for:

• Academic Pathologists
• Community Pathologists
• Hematopathologists
• Pathologists-in-Training
• Pathology Residents
• Pathology Fellows
• Healthcare professionals specializing in hematopathology

Why This Course Is Valuable

USCAP 2026 Hematopathology Update addresses one of the most important challenges in modern hematopathology: integrating increasingly sophisticated molecular and ancillary technologies while maintaining strong morphologic diagnostic skills.

By focusing on the practical application of the WHO 5th Edition and ICC, the program helps pathologists navigate contemporary classification systems, recognize important diagnostic differences, select appropriate ancillary studies, and integrate all available evidence into an accurate final diagnosis.

+ Topics:

• Reactive Lymph Nodes – Amy Chadburn, MD

• Plasma Cell Neoplasms – Robert Lorsbach, MD, PhD

• Bone Marrow B-Cell Lymphomas (CLL, Mantle, Hairy Cell, SMZL, LPL) and SLL (+Richters) – Laurence L. de Leval, MD, PhD

• Follicular Lymphoma and Nodal Marginal Zone Lymphoma – Ioannis Anagnostopoulos, MD

• Extranodal B-Cell Lymphomas and Splenic Lymphomas – Judith A. Ferry, MD

• Burkitt and High-Grade Lymphoma/DLBCL – Amy Chadburn, MD

• The Many Other Faces of DLBCL – Judith A. Ferry, MD

• Hodgkin Lymphoma and Related Entities – Ioannis Anagnostopoulos, MD

• Immunodeficiency and Fluid-Based B-Cell Lymphomas – Amy Chadburn, MD

• Peripheral T-Cell Lymphoma #1 – Laurence L. de Leval, MD, PhD

• Peripheral T-Cell Lymphoma #2 – Laurence L. de Leval, MD, PhD

• Cutaneous T-Cell and B-Cell Lymphomas – Judith A. Ferry, MD

• Non-Neoplastic Bone Marrow Conditions – Robert P. Hasserjian, MD

• Myeloproliferative Neoplasms – Daniel A. Arber, MD

• Myelodysplastic Syndromes/Neoplasms and Clonal Cytopenias – Robert P. Hasserjian, MD

• Pediatric Myeloid Neoplasms and Germline Conditions – Robert Lorsbach, MD, PhD

• Acute Myeloid Leukemia – Joseph D. Khoury, MD

• B- and T-Lymphoblastic Leukemia/Lymphoma – Robert Lorsbach, MD, PhD

• Histiocytic and Dendritic Neoplasms – Joseph D. Khoury, MD

• Mixed Phenotype Acute Leukemias and Eosinophilic Neoplasms – Joseph D. Khoury, MD

• Systemic Mastocytosis – Daniel A. Arber, MD

• Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) – Daniel A. Arber, MD

• Evaluation of Progressed and Treated Myeloid Neoplasms – Robert P. Hasserjian, MD

• FREE SECTION: Panel Q&A Sessions